Alaref A, Siltamaki D, Cerasuolo JO, Akhtar-Danesh N, Caswell JM, Serrano PE, Meyers BM, Savage DW, Nelli J, Patlas M, Alabousi A, Siddiqui R, and van der Pol CB
Background: This study determined the impact of pre-operative abdominal MRI on all-cause mortality for patients with resected PDAC., Methods: All adult (≥18 years) PDAC patients who underwent pancreatectomy between January 2011 and December 2022 in Ontario, Canada, were identified for this population-based cohort study (ICD-O-3 codes: C250, C251, C252, C253, C257, C258). Patient demographics, comorbidities, PDAC stage, medical and surgical management, and survival data were sourced from multiple linked provincial administrative databases at ICES. All-cause mortality was compared between patients with and without a pre-operative abdominal MRI after controlling for multiple covariates., Findings: A cohort of 4579 patients consisted of 2432 men (53.1%) and 2147 women (46.9%) with a mean age of 65.2 years (standard deviation: 11.2 years); 2998 (65.5%) died while 1581 (34.5%) survived. Median follow-up duration post-resection was 22.4 months (interquartile range: 10.8-48.8 months), and median survival post-pancreatectomy was 25.9 months (95% confidence interval [95% CI]: 24.8, 27.5). Patients who underwent a pre-operative abdominal MRI had a median survival of 33.1 months (95% CI: 30.7, 37.2) compared to 21.1 months (95% CI: 19.8, 22.6) for all others. A total of 2354/4579 (51.4%) patients underwent a pre-operative abdominal MRI, which was associated with a 17.2% (95% CI: 11.0, 23.1) decrease in the rate of all-cause mortality, with an adjusted hazard ratio (aHR) of 0.828 (95% CI: 0.769, 0.890)., Interpretation: Pre-operative abdominal MRI was associated with improved overall survival for PDAC patients who underwent pancreatectomy, possibly due to better detection of liver metastases than CT., Funding: Northern Ontario Academic Medicine Association (NOAMA) Clinical Innovation Fund., Competing Interests: Dr. Brandon Meyers has received research support from Abbvie, ALX, Astra-Zeneca, GSK, Eisai, Roche, advises Amgen, Astra-Zeneca, Bayer, BMS, Eisai, EMD Serono, Incyte, Ipsen, Merck, Roche, Sanofi Genzyme, Servier, is an expert consultant for Roche, CADTH, Cancer Care Ontario (CCO), Health Canada, and has received travel stipends from Eisai and Ipsen; Dr. David W. Savage is a co-investigator and a Principal Investigator on a Northern Ontario Academic Medicine Association (NOAMA) grant, a co-investigator on a Canadian Institutes of Health Research (CIHR) grant and is the Interim Site Director of ICES North; Dr. Pablo E. Serrano has provided consulting services for Incyte Biosciences Canada and received an honorarium from Hoffman La Roche; and Dr. Michael Patlas receives royalties from Elsevier. None of the other authors have conflicts of interest to disclose. This study was supported by ICES, which is funded by an annual grant from the Ontario Ministry of Health (MOH) and the Ministry of Long-Term Care (MLTC). This document used data adapted from the Statistics Canada Postal CodeOM Conversion File, which is based on data licensed from Canada Post Corporation, and/or data adapted from the Ontario Ministry of Health Postal Code Conversion File, which contains data copied under license from ©Canada Post Corporation and Statistics Canada. Parts of this material are based on data and/or information compiled and provided by Ontario Health (OH), Canadian Institute for Health Information (CIHI), and the Ontario MOH. The analyses, conclusions, opinions, and statements expressed herein are solely those of the authors and do not reflect those of the funding or data sources; no endorsement is intended or should be inferred., (© 2024 The Author(s).)